Quiz

Article

Clinician Quiz: Hepatitis C Treatment Recommendation Updates

Digital illustration of a clinician (hepatologist) standing next to a liver. | Credit: Pixabay (Mohamed_hassan)

Credit: Pixabay (Mohamed_hassan)

Thanks to advances in technology and pharmacotherapy, the diagnosis and management of hepatitis C virus has evolved greatly in recent years.

In 2023, the American Association for the Study of Liver Diseases partnered with the Infectious Diseases Society of America to develop a focused update to guidance published in 2020. An 18-page document citing more than 160 references, the focused update spotlights major changes related to screening, organ transplant, and expanded treatment options for children and adolescents.

Test your knowledge of these updates in the quiz below:

What are the recommended DAA regimens for HCV treatment-naive adults without cirrhosis according to the simplified treatment approach?


References:

  1. Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel . Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. Published online May 25, 2023. doi:10.1093/cid/ciad319

Editors' note: Artificial intelligence aided in the creation of this content.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.